Leukemia Research
Volume 27, Issue 5 , Pages 375-380 , May 2003

Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFα levels during treatment

  • Apostolia-Maria Tsimberidou

      Affiliations

    • Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    • ,
  • Tracey Waddelow

      Affiliations

    • Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    • ,
  • Hagop M Kantarjian

      Affiliations

    • Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    • ,
  • Maher Albitar

      Affiliations

    • Department of Hematopathology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    • ,
  • Francis J Giles

      Affiliations

    • Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-713-792-8217; fax: +1-713-794-4297.

Received 28 January 2002 ,Accepted 23 April 2002.

References 

  1. Giles FJ. Multiple myeloma and other differentiated B-cell disorders. Curr. Opin. Hematol. 1994;1:278–284
  2. Giles FJ. Refractory multiple myeloma: recent advances in therapy. Hematol. Pathol. 1995;9:121–140
  3. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. New Engl. J. Med. 1984;310:1353–1356
  4. Barlogie B, Desikan R, Eddlemon P, et al.  Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a Phase 2 study of 169 patients. Blood. 2001;98:492–494
  5. Singhal S, Mehta J, Desikan R, et al.  Anti-tumor activity of thalidomide in refractory multiple myeloma. New Engl. J. Med. 1999;341:1565–1571
  6. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur. Cytokine Network. 1999;10:65–70
  7. Hallek M, Leif Bergsagel P, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3–21
  8. Borset M, Waage A, Brekke OL, Helseth E. TNF and IL-6 are potent growth factors for OH-2: a novel human myeloma cell line. Eur. J. Haematol. 1994;536:31–37
  9. Borset M, Medvedev A, Sundan A, Espevik T. The role of the two TNF receptors in proliferation, NF-Kappa B activation and discrimination between TNF and LT α signalling in the human myeloma cell line OH-2. Cytokine. 1996;8:430–438
  10. Hata H, Matsuzaki H, Takatsuki K. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor α, in the myeloma cell line KHM-1A. Acta Haematol. 1990;83:133–136
  11. Filella X, Blade J, Guillermo A, Molina R, Rozman C, Ballesta A. Cytokines (IL-6, TNFα, IL-1α) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Ca Detecti. Prevent. 1996;20:52–56
  12. Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG. An interleukin-1 like factor stimulates bone resorption in vitro. Nature. 1983;306:378–380
  13. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986;319:516–518
  14. Torcia M, Lucibello M, Edouard V, et al.  Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp. Hematol. 1996;24:868–874
  15. Bataille R. New insight in the clinical biology of myltiple myeloma. Sem. Hematol. 1997;34:23–28
  16. Gazitt Y, Tian E, Barlogie B, et al.  Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood. 1996;87:805–811
  17. Lichtenstein A, Berenson JR, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood. 1989;74:1266–1273
  18. Smith CA, Davis T, Anderson D, et al.  A receptor for tumor necosis factor defines an unusual family of cellular and viral proteins. Science. 1990;248:1019–1023
  19. Loetscher H, Pan YC, Lahm HW, et al.  Molecular cloning and expression of the human 55 kDa tumor necrosis factor receptor. Cell. 1990;61:351–359
  20. Mohler KM, Torrance DS, Smith CA, et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 1993;151:1548–1561
  21. Moreland LW, Baumgartner SW, Schiff MH, et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New Engl. J. Med. 1997;337:141–147
  22. Moreland LW, Schiff MH, Baumgartner SW, et al.  Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 1999;130:478–486
  23. Skytta E, Pohjankoski H, Savolainen A, et al.  Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2000;18:533–534
  24. Spencer-Green G. Etanercept (Enbrel): update on therapeutic use. Ann. Rheum. Dis. 2000;59:i46–49
  25. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener’s granulomatosis: a 6 months open-label trial to evaluate safety. Arthritis Rheum. 2001;44:1149–1154
  26. Nam MH, Reda D, Boujoukos AJ, Agosti J, Suffredini AF. Recombinant soluble tumor necrosis factor (TNF) receptor (TNFC:Fc): safety and pharmacokinetics in human volunteers. Clin Res 1993;41.
  27. Bozkurt B, Torre-Amione G, Warren MS, et al.  Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation. 2001;103:1044–1047
  28. Deswal A, Bozkurt B, Seta Y, et al.  Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999;99:3224–3226
  29. Fisher CJJ, Agosti JM, Opal SM, et al.  Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. New Engl. J. Med. 1996;334:1697–1702
  30. Abraham E, Wunderink R, Silverman H. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA. 1995;273:934–941
  31. Carlet J, Cohen J, Andersson J, et al. INTERSEPT: an international efficacy and safety study of monoclonal antibody to human tumor necrosis factor (hTNF) in patients with the sepsis syndrome. In: Proceedings of the Program and Abstracts of the 34th Interscience Conference on Anti-microbial Agents and Chemotherapy. American Society for Microbiology. Orlando, FL, 1994.
  32. Institute NC. Guidelines for reporting of adverse drug reactions. Bethesda (MD): Division of Cancer Treatment, National Cancer Institute, 1998.
  33. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting features, response to treatment, and survival. Cancer. 1975;36:842
  34. Alldred A. Etanercept in rheumatoid arthritis. Exp. Opin. Pharmacother. 2001;2:1137–1148
  35. Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: what we have learned?. Ann. Rev. Immunol. 2001;19:163–196
  36. Eason JD, Pascual M, Wee S, et al.  Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation. 1996;61:224–228
  37. Neben K, Mytilineos J, Moehler TM, et al. Genetic polymorphism in the tumor necrosis factor-α locus influences the outcome to thalidomide therapy in relapsed and refractory multiple myeloma, vol. 98. Blood. Orlando: ASH, 2001.
  38. Sivaraman S, Deshpande G, Tao M, et al. Effect of in vitro administration of TNF receptor fusion protein (TNFR:Fc) on the biological characteristics of AML cells, vol. 96. Blood. San Francisco (CA): ASH, 2000.
  39. Raza A, Dutt D, Lisak L, et al. Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic Syndromes, vol. 96. Blood. Orlando: ASH, 2001.
  40. Steensma DP, Mesa RA, Li CY, et al. Etanercept palliates constitutional symptoms in myelofibrosis with myeloid metaplasia: Results of a Pilot Study, vol. 96, Blood. Orlando: ASH. 2001.
  41. Tsimberidou AM, Thomas DA, O’Brien S, et al. Recombinant human soluble tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory hematological malignancies, vol. 98. Orlando: ASH, 2001.

PII: S0145-2126(02)00082-6

doi: 10.1016/S0145-2126(02)00082-6

Leukemia Research
Volume 27, Issue 5 , Pages 375-380 , May 2003

Article Tools